Atai Life Sciences Past Earnings Performance
Past criteria checks 0/6
Atai Life Sciences has been growing earnings at an average annual rate of 10.7%, while the Pharmaceuticals industry saw earnings growing at 8.4% annually. Revenues have been declining at an average rate of 121.6% per year.
Key information
10.7%
Earnings growth rate
35.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | -121.6% |
| Return on equity | -16.5% |
| Net Margin | -12,202.9% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Atai Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -34 | 61 | 53 |
| 31 Dec 23 | 0 | -40 | 62 | 60 |
| 30 Sep 23 | 0 | -67 | 58 | 68 |
| 30 Jun 23 | 0 | -145 | 64 | 74 |
| 31 Mar 23 | 0 | -149 | 65 | 76 |
| 31 Dec 22 | 0 | -152 | 70 | 74 |
| 30 Sep 22 | 0 | -196 | 81 | 65 |
| 30 Jun 22 | 1 | -194 | 81 | 60 |
| 31 Mar 22 | 0 | -205 | 101 | 58 |
| 31 Dec 21 | 20 | -168 | 93 | 48 |
| 30 Sep 21 | 20 | -166 | 139 | 38 |
| 30 Jun 21 | 20 | -218 | 123 | 33 |
| 31 Mar 21 | 20 | -185 | 88 | 15 |
| 31 Dec 20 | 0 | -170 | 81 | 11 |
Quality Earnings: 9VC is currently unprofitable.
Growing Profit Margin: 9VC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 9VC is unprofitable, but has reduced losses over the past 5 years at a rate of 10.7% per year.
Accelerating Growth: Unable to compare 9VC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 9VC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.2%).
Return on Equity
High ROE: 9VC has a negative Return on Equity (-16.54%), as it is currently unprofitable.